A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

BACKGROUND: Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO)...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Noguchi, Masanori, Moriya, Fukuko, Suekane, Shigetaka, Ohnishi, Rei, Matsueda, Satoko, Sasada, Tetsuro, Yamada, Akira, Itoh, Kyogo
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2013
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882108/
https://ncbi.nlm.nih.gov/pubmed/24373380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-613
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים